Key result
Emerging physiological and molecular markers show potential to improve CV risk stratification in OSA.
Why the study?
Findings linking obstructive sleep apnoea to cardiovascular health remain controversial, likely due to patient heterogeneity, requiring additional information to better stratify patients according to cardiovascular risk.
Can physiology-based metrics and blood-based molecular markers improve cardiovascular risk stratification in patients with obstructive sleep apnoea?
Can physiology-based metrics and blood-based molecular markers improve cardiovascular risk stratification in patients with obstructive sleep apnoea?
Novel physiology-based and blood-based biomarkers may improve cardiovascular risk stratification and treatment allocation in patients with obstructive sleep apnoea.
These markers may aid OSA risk stratification; hypothesis-generating and require prospective validation before practice change.
PURPOSE OF REVIEW: Obstructive sleep apnoea (OSA) is the most common form of sleep-disordered breathing and has been linked to cardiovascular health. However, some of the findings supporting this are controversial. These discrepancies might be a result of heterogeneity among OSA patients, and thus, additional information would be required to better stratify OSA patients according to cardiovascular risk. In this review, we aim to discuss the potential of biomarkers to fulfil this role. RECENT FINDINGS: Randomized controlled trials have been unable to confirm whether OSA treatment with continuous positive airway pressure (CPAP) has a positive effect on cardiovascular outcomes. Emerging physiology-based metrics of OSA seem to be more suitable for identifying patients at higher risk of cardiovascular disease and predicting the effects of CPAP outcomes on cardiovascular health. Similarly, blood-based molecular markers have gained attention in this context over the last few years. SUMMARY: Accurate cardiovascular risk stratification and appropriate treatment allocation for OSA patients remain challenging. However, significant efforts are being made to develop novel tools to address these important issues.
No takes yet. Share an insight, caveat, or question.
Dodani et al. (2024) conducted a review in Obstructive sleep apnoea (OSA). Biomarkers and physiology-based metrics was evaluated. Emerging physiology-based metrics and blood-based molecular markers show potential for better cardiovascular risk stratification in patients with obstructive sleep apnoea.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: